Buscar
Pliant Therapeutics Inc
PLRXAñadir a la lista de seguimiento
1.090USD
+0.010+0.93%
Cierre 07-24 16:00（ET）Cotizaciones retrasadas 15 min
67.49MCap. mercado
PérdidaP/E TTM
Más Datos de Pliant Therapeutics Inc Compañía
Pliant Therapeutics, Inc. is a late-stage biotechnology company, which is focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. The Company’s lead product candidate, bexotegrast (PLN-74809), is an oral, small molecule, dual selective inhibitor of avb6 and avb1 integrins that is in development in the lead indication for the treatment of idiopathic pulmonary fibrosis, or idiopathic pulmonary fibrosis (IPF). The Company’s second clinical program, PLN-101095, is a small molecule, dual selective inhibitor of integrins avb8 and avb1 for the treatment of solid tumors that are resistant to immune checkpoint inhibitors. Its Phase 1-ready program PLN-101325, is in development for treatment of muscular dystrophies, including Duchenne muscular dystrophy. PLN-101325 is a monoclonal antibody designed to act as an allosteric agonist of integrin a7b1.
Información de Pliant Therapeutics Inc
Símbolo de cotizaciónPLRX
Nombre de la empresaPliant Therapeutics Inc
Fecha de salida a bolsaJun 03, 2020
Director ejecutivoCoulie (Bernard J)
Número de empleados171
Tipo de seguridadOrdinary Share
Fin del año fiscalJun 03
Dirección331 Oyster Point Boulevard
CiudadSOUTH SAN FRANCISCO
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal94080
Teléfono16504816770
Sitio Webhttps://pliantrx.com/
Símbolo de cotizaciónPLRX
Fecha de salida a bolsaJun 03, 2020
Director ejecutivoCoulie (Bernard J)
Ejecutivos de Pliant Therapeutics Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Bernard J. Coulie, M.D., Ph.D.
Dr. Bernard J. Coulie, M.D., Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
766.87K
+19.64%
Dr. Hoyoung Huh, M.D., Ph.D.
Dr. Hoyoung Huh, M.D., Ph.D.
Non-Executive Chairman of the Board, Lead Independent Director
Non-Executive Chairman of the Board, Lead Independent Director
99.76K
--
Dr. Suzanne Louise (Sue) Bruhn, Ph.D.
Dr. Suzanne Louise (Sue) Bruhn, Ph.D.
Independent Director
Independent Director
35.08K
--
Dr. John T. Curnutte, M.D., Ph.D.
Dr. John T. Curnutte, M.D., Ph.D.
Independent Director
Independent Director
29.28K
--
Ms. Lily Cheung
Ms. Lily Cheung
Chief Human Resources Officer
Chief Human Resources Officer
18.93K
+61.88%
Dr. Eric Lefebvre, M.D.
Dr. Eric Lefebvre, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Keith Cummings, M.D.
Dr. Keith Cummings, M.D.
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Gayle Crowell
Ms. Gayle Crowell
Independent Director
Independent Director
--
--
Mr. Christopher Keenan
Mr. Christopher Keenan
Vice President - Investor Relations and Corporate Communications
Vice President - Investor Relations and Corporate Communications
--
--
Mr. David E. I. Pyott, CBE
Mr. David E. I. Pyott, CBE
Independent Director
Independent Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Bernard J. Coulie, M.D., Ph.D.
Dr. Bernard J. Coulie, M.D., Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
766.87K
+19.64%
Dr. Hoyoung Huh, M.D., Ph.D.
Dr. Hoyoung Huh, M.D., Ph.D.
Non-Executive Chairman of the Board, Lead Independent Director
Non-Executive Chairman of the Board, Lead Independent Director
99.76K
--
Dr. Suzanne Louise (Sue) Bruhn, Ph.D.
Dr. Suzanne Louise (Sue) Bruhn, Ph.D.
Independent Director
Independent Director
35.08K
--
Dr. John T. Curnutte, M.D., Ph.D.
Dr. John T. Curnutte, M.D., Ph.D.
Independent Director
Independent Director
29.28K
--
Ms. Lily Cheung
Ms. Lily Cheung
Chief Human Resources Officer
Chief Human Resources Officer
18.93K
+61.88%
Dr. Eric Lefebvre, M.D.
Dr. Eric Lefebvre, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Pliant Therapeutics Inc?
Los cinco principales accionistas de Pliant Therapeutics Inc son: Dr. Bernard J. Coulie, M.D., Ph.D.
¿Cuántas instituciones poseen acciones de Pliant Therapeutics Inc (PLRX)?
A fecha de 2026Q1, 360 instituciones poseen acciones de Pliant Therapeutics Inc, con un valor de mercado combinado de aproximadamente 50.65M, lo que representa el 81.81% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en -48746249.00.